Adverse Event Management

Brain Cancer

Breast Cancer

Disparities in Cancer Care

Drug Safety

Colorectal Cancer

Liver Cancer

Gastric Cancers

Gastrointestinal Cancer

Genetics

Kidney Carcinoma

Bladder Cancer

Prostate Cancer

Genitourinary Cancer

Endometrial Cancer

Cervical Cancer

Ovarian Cancer

Gynecologic Cancers

Head and Neck Cancers

Leukemia

Multiple Myeloma

Lymphoma

Hematology

Immuno-Oncology

Lung Cancer

Myeloproliferative Neoplasms

Nurse Navigation

Pediatric Cancer

Prevention

Radiation Oncology

Sarcomas

Melanoma

Skin Cancer

Supportive Care

Survivorship

Patients who received pomalidomide, bortezomib, and dexamethasone achieved a median overall survival of 35.6 months compared with 31.6 months among patients treated with bortezomib and dexamethasone. 

PVd Confers a Small OS Benefit to Patients With Relapsed/Refractory Multiple Myeloma

Patients with EGFR-mutated non–small cell lung cancer had a median event-free survival of 30.8 months in the durvalumab arm and 19.6 months in the placebo arm.

Neoadjuvant Durvalumab Combination Misses Mark in EGFR+ NSCLC

Findings from the PACIFIC-R trial showed that patients with EGFR-mutated non-small cell lung cancer experienced shorter progression-free survival with durvalumab than patients with EGFR-wildtype disease. 

Durvalumab Garners Similar OS, Albeit Varied PFS, Outcomes in EGFR+ and EGFR-Wildtype NSCLC Subgroups 

Quizartinib plus standard intensive induction and consolidation therapy was associated with longer survival rates in patients with FLT3-ITD–positive acute myeloid leukemia. 

Quizartinib Extends Overall Survival Across Multiple Subgroups in FLT3-ITD+ AML 

News

Latest News

FDA News

Survivorship 

Practice Management

Contributers

Media

Medical World News

Podcasts

Videos

Conferences

Conference Coverage

Conference Listing

Publications

CME/CE

Cancer Insight Summary Slides

Continuing Education

Resources

Oncology Drug Crash Course

Webinars

Cancer Summary Slides

Subscribe

Partners

Elizabeth Aronson, MSN, FNP-BCN, OCN, shares what stood out to her about the phase 2 MagnetisMM-3 trial assessing elranatamab in multiple myeloma. 

Elizabeth Aronson Walks Through the Data Supporting Elranatamab Approval in Multiple Myeloma

Articles

Resistance training and walking can be beneficial for patients with multiple myeloma. 

Ambulation Improves Frailty Scores in Patients With Multiple Myeloma

In a single-center retrospective analysis, the median progression-free survival among patients with multiple myeloma treated with teclistamab was 4.7 months. 

Real-World Experiences With Teclistamab Are Comparable To Clinical Trial Reports

CancerNetwork.com

CureToday.com

OncLive.com

TargetedOnc.com

Privacy

Terms & Conditions

Do Not Sell My Information

Oncology Nursing News

Facebook

Twitter

Specialty

Advanced Practice Providers

Clinical

Gynecologic Cancer

Immunotherapy

Quality Improvement

1rem

Advances In™: Meeting Unmet Clinical Needs in AML with Evolving Therapeutic Approaches

ACCC 40th National Oncology Conference Pre-Session: Clinical Updates from Chicago – A Focus on What Community Centers Need to Know to Move Their Solid Tumors' Practices Forward

Reflective Case-Based Oncology Collective: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care

Antibody-Drug Conjugates in Gynecological Cancer – Setting the Stage

Lynette M. Sholl, MD; Justin F. Gainor, MD; Fred R. Hirsch, MD, PhD, FASCO

Catching Them Early: A Real-World Case Discussion on the Application of Testing Methodologies to Identify Key Markers Across NSCLC

20th Annual Meeting of the International Society of Gastrointestinal Oncology®

Steven Horwitz, MD; Ellen J. Kim, MD; Alison Moskowitz. MD

Medical Crossfire®: Diagnostic and Clinical Considerations in Cutaneous T-Cell Lymphoma for the Dermatologist and the Collaborative Cancer Team

Shakeel Modak, MD, MRCP; Araz Marachelian, MD, MS

Advances In™ Pediatric Neuroblastoma: Exploring Current and Emerging Therapeutic Approaches for Relapsed/Refractory Disease and CNS Metastases

5th Annual Precision Medicine Symposium: An Illustrated Tumor Board

2022 BURST Year in Review™: Reflecting on Recent Evidence for Testing in Patients with GI Cancers

Burst CME: Regulatory Approval Pathways for Influenza Vaccines

John Mascarenhas, MD; Heinz Gisslinger, MD; Kathryn Johnson, DNP, MSc, FNP-BC; Naveen Pemmaraju, MD


4th Annual Virtual Tumor Board®: Diagnosis and Management of Polycythemia Vera and Myelofibrosis

Grace Cherry, MSN, RN, NP; Beth Sandy, MSN, CRNP; Laura S. Wood, MSN, RN, OCN; Patricia Mangan, MSN, RN, CRNP, APRN-BC; Kimberly Podsada, MSN, NP-C; Rowena “Moe” Schwartz, PharmD, BCOP,
FHOPA



Community Practice Connections™: 6th Annual School of Nursing Oncology

Antibody-Drug Conjugates in Gynecological Cancer: Review of the Clinical Data

Hope S. Rugo, MD, FASCO; Giuseppe Curigliano, MD, PhD; Özge Gümüşay, MD

  Expanding Options Beyond Conventional Therapy in HR+ Breast Cancer to Overcome Unmet Needs

Srdan Verstovsek, MD, PhD; Lucia Masarova, MD; Jeanne Palmer, MD; Abdulraheem Yacoub, MD   

Medical Crossfire®:  Experts Address Your Burning Questions on the Evolving Treatment of MF, PV, and ET!

Nikolai A. Podoltsev, MD, PhD; John Mascarenhas, MD

Oncology Consultations®: Leveraging Clinical Data and Trials to Inform Treatment for Patients with PV

41st Annual CFS®: Innovative Cancer Therapy for Tomorrow®

Heather A. Wakelee, MD, FASCO; Lyudmila Bazhenova, MD; Kristin Higgins, MD; Brendon Stiles, MD

  Medical Crossfire: How Should We Leverage Multidisciplinary Lung Cancer Care Teams in Managing Earlier Forms of NSCLC... When the Goal Is Cure?

Charu Aggarwal, MD, MPH; David R. Gandara, MD; Lynette M. Sholl, MD; Ignacio I. Wistuba, MD

Virtual Testing Board: Digging Deeper on Your Testing Reports to Elevate Patient Outcomes in Advanced Non–Small Cell Lung Cancer

Upcoming CME Events & Activities

EVENTS

ACTIVITIES

Latest Conference Coverage